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Abstract
Until an effective vaccine against SARS- CoV-2 is available on a widespread scale, the control of the COVID-19 pandemic is 
reliant upon effective pandemic control measures. The ability of SARS- CoV-2 to remain viable on surfaces and in aerosols, 
means indirect contact transmission can occur and there is an opportunity to reduce transmission using effective disinfectants 
in public and communal spaces. Virusend (TX-10), a novel disinfectant, has been developed as a highly effective disinfectant 
against a range of microbial agents. Here we investigate the ability of Virusend to inactivate SARS- CoV-2. Using surface and 
solution inactivation assays, we show that Virusend is able to reduce SARS- CoV-2 viral titre by 4 log
10
 p.f.u. ml−1 within 1 min of 
contact. Ensuring disinfectants are highly effective against SARS- CoV-2 is important in eliminating environmental sources of 
the virus to control the COVID-19 pandemic.
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-
 CoV-2) is a novel coronavirus that is the causative agent of 
COVID-19 which first emerged in late 2019 [1]. Countries 
are working to control transmission of SARS- CoV-2 with the 
ultimate goal of production and large- scale manufacture of 
effective vaccines [2–4]. Until an effective vaccine is widely 
distributed, control of the virus is limited to implementing 
measures such as contact tracing, quarantine, enforcing strict 
social distancing, advising frequent hand hygiene and infec-
tion control measures in hospital environments [5]. During 
the 2002 outbreak of SARS- CoV-1, and the 2012 Middle East 
respiratory syndrome- related (MERS)- CoV outbreak, virus 
stability on environmental surfaces facilitated transmission 
events [6]. Similarly, research has shown that SARS- CoV-2 
can remain viable on surfaces, notably plastic and stainless 
steel for up to 72 h post- inoculation, and in aerosols for at 
least 3 h, meaning effective disinfectants can prevent indi-
rect contact transmission [7]. Virusend (TX-10) has been 
developed to work as a highly effective disinfectant that 
rapidly inactivates enveloped viruses. As communities begin 
to reopen and people return to the workplace, effective and 
quick disinfection of communal areas is paramount to main-
taining control of COVID-19. Here we present the evidence 
that Virusend can reduce SAR- CoV-2 virus within 1 min both 
in solution and on surfaces.
METHODS
Cell culture and viruses
Vero E6 cells (C1008: African green monkey kidney cells), 
obtained from Public Health England, were maintained in 
Dulbecco’s minimal essential medium (DMEM) containing 
10 % foetal bovine serum (FBS) and 0.05 mg ml−1 gentamicin. 
Cells were kept at 37 °C with 5 % CO2. Passage four or five 
of a SARS- CoV-2 isolate (REMRQ0001/Human/2020/Liver-
pool) from a clinical sample was used to assess inactivation 
of Virusend. On the fourth and fifth passages the virus was 
cultured in Vero E6 cells maintained in DMEM with 4 % 
FBS and 0.05 mg ml−1 gentamicin at 37 °C and 5 % CO2 as 
previously described [8]. The fifth passage of the virus was 
harvested 48 h after inoculation and concentrated by passage 
through a centrifugal column (Amicon Ultra-15 100 kDa 
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Virus inactivation
Inactivation on surfaces were performed using either 9.8 log10 
or 7.9 log10 p.f.u. ml
−1 of SARS- CoV-2. Surface inactivation 
was carried out by inoculating the hard surface, stainless 
steel discs, with 50 µl of virus and allowed to air dry at room 
temperature for 1 h. Dried inoculum was incubated with 100 µl 
of Virusend (TX-10; Virusend was developed by Pritchard 
Spray Technologies, Colchester, UK) or autoclaved water for 
control samples for either 30 s or 9.5 min, after which 900 µl 
of DMEM containing 2 % FBS and 0.05 mg ml−1 gentamicin 
was added and mixed until dried inoculum was dissolved. The 
sample was then transferred into a dilution series for virus 
quantification at exactly 1 min or 10 min after addition of 
Virusend to the dried inoculum. Solution inactivation assays 
used either 8.4 log10 or 7.9 log10 p.f.u. ml
−1 and were carried 
out by incubating 25 µl of inoculum with 100 µl of Virusend 
or autoclaved water for control samples for either 1 min or 
10 min. After incubation, 10 ml of DMEM was added and 
transferred to a dilution series within 30 s of DMEM being 
added. All experiments were performed in duplicate.
Cytotoxicity assay
Cytotoxicity for surface inactivation was determined by inoc-
ulating stainless steel discs with 50 µl of DMEM containing 
2 % FBS and 0.05 mg ml−1 gentamicin and allowed to air dry 
at room temperature for 1 h. Dried inoculum was incubated 
with 100 µl of Virusend or autoclaved water for 5 min, after 
which 900 µl of DMEM containing 2 % FBS and 0.05 mg ml−1 
gentamicin was added and mixed until dried inoculum was 
dissolved. The sample was then transferred into a dilution 
series and a standard plaque assay performed. Cytotoxicity for 
solution assays were performed by incubating 25 µl of DMEM 
containing 2 % FBS and 0.05 mg ml−1 gentamicin with 100 µl 
of Virusend for 5 min, after which 10 ml of DMEM was added 
and sample transferred to a dilution series for standard plaque 
assays. The cytotoxicity assays were performed in duplicate.
Suppression assay
Suppression for solution inactivation was assayed by adding 
25 µl of inoculum, either 8.4 log10 or 7.9 log10 p.f.u. ml
−1, to 
100 µl of Virusend in 10 ml of DMEM and incubated for 30 s. 
After 30 s, the sample was transferred into a dilution series 
and a standard plaque assay performed. The suppression assay 
was performed in duplicate.
Virus quantification and viability
Samples from each condition were serial diluted 10- fold for 
quantification by standard plaque assay using Vero E6 cells 
[9]. Cells were incubated for 72 h at 37 °C and 5 % CO2, then 
fixed with 10 % formalin and stained with 0.05 % crystal violet 
solution. Plaques were counted to calculate virus titre. All 
samples were performed in technical duplicates.
RESULTS
For inactivation assays, Virusend was directly placed on 
SARS- CoV-2 inoculum, for an incubation period of either 
1 min or 10 min. On the hard surface (stainless steel disc), 
contact time of 1 min with Virusend reduced SARS- CoV-2 
titres to below the limit of detection for both high and low 
titre inoculum (Fig. 1). A titre of 7.3 log10 p.f.u. ml
−1 was 
recovered from the high titre, hard surface control samples. 
Similarly, incubation with Virusend for 10 min reduced the 
virus titre to below the limit of detection, compared with 7.0 
log10 p.f.u. ml
−1 recovered from the high titre control. With a 
low titre inoculum, Virusend also reduced SARS- CoV-2 titres 
to below the limit of detection after contact times of 1 and 
10 min on hard surfaces. Titres of 5.3 log10 p.f.u. ml
−1 and 5.9 
log10 p.f.u. ml
−1 were recovered from the 1 and 10 min control 
samples, respectively. Cytotoxicity assays with Virusend in the 
absence of virus were used to determine the limit of detection, 
the point at which Vero E6 cell death is due to the cytotoxicity 
of Virusend, and not virus. Cytopathic effect was observed to 
3.0 log10 p.f.u. ml
−1 (Fig. 1). Both inactivation and cytotoxicity 
assays confirm a reduction of at least 4.0 log10 p.f.u. ml
−1 of 
infectious SARS- CoV-2 with high titre inoculum and a reduc-
tion of at least 2.3 log10 p.f.u. ml
−1 with low titre inoculum 
(Fig. 1).
For inactivation assays in solution, Virusend was placed 
directly into solution with SARS- CoV-2 for either 1 or 10 min. 
An incubation period of 1 min with Virusend reduced the 
high titre inoculum by 4.0 log10 p.f.u. ml
−1, from 6.0 log10 
p.f.u. ml−1 in the water control to below the limit of detection 
(Fig. 2). A 10 min incubation with Virusend also reduced 
Fig. 1. Virusend (TX-10) reduces viral titre on hard surfaces by at least 
4.0 log
10
 p.f.u. ml−1 with high titre (HT) viral inoculum after contact times 
of 1 min and 10 min. When low titre (LT) inoculum was used, Virusend 
reduces virus titre by at least a 2.3 log
10
 p.f.u. ml−1 at both 1 min and 
10 min contact time. Diagonal pattern represents cytopathic effect 
caused by TX-10 and solid black represents the titre of infectious virus 
following each treatment. Limit of detection (LOD) (3.0 log
10
 p.f.u. ml−1) 
is shown across the graph with a dotted red line. All columns represent 
mean of n=2,±SD.
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viral titre by 4.0 log10 p.f.u. ml
−1, from 6.0 log10 p.f.u. ml
−1 to 
below the limit of detection. With the low titre inoculum, 
the addition of Virusend reduced SARS- CoV-2 to below the 
limit of detection at both 1 min and 10 min incubation times, 
reductions of 3.6 log10 p.f.u. ml
−1 (Fig. 2). Titres of 5.6 log10 
p.f.u. ml−1 were recovered from control samples at 1 min and 
10 min. A suppression assay for solution inactivation assays 
was used to demonstrate that dilution with 10 ml of DMEM 
suppressed Virusend inactivation of SARS- CoV-2 upon the 
completion of the assay. The addition of virus inoculum to 
Virusend in 10 ml of DMEM recovered a virus titre of 5.7 
log10 p.f.u. ml
−1 with high titre inoculum and 5.6 log10 p.f.u. 
ml−1 with low titre inoculum. Cytotoxicity assays for solution 
inactivation assays showed the limit of detection for these 
assays was 2.0 log10 p.f.u. ml
−1.
DISCUSSION
SARS- CoV-2 can remain viable on surfaces, notably plastic 
and stainless steel, for up to 72 h post- inoculation, and 
in aerosols for at least 3 h [7]. In solutions, SARS- CoV-2 
may remain viable for up to 14 days at 4 °C, 7 days at room 
temperature, and for 1 to 2 days at 37 °C [10]. Therefore, 
contaminated surfaces and solutions are a reservoir for 
transmission through fomites, meaning effective hygiene 
and environmental decontamination is crucial in helping 
to prevent the spread of COVID-19 [11, 12]. Disinfectant 
solutions of 75 % ethanol and 10 % sodium hypochlorite are 
able to reduce SARS- CoV-2 titre by at least 2.0 log10 TCID50 
ml−1 and 3.25 log10 TCID50 ml
−1, respectively, within 5 min 
[10, 13]. However, the World Health Organization (WHO) 
has recommended diluting household bleach 1 : 100 to reduce 
irritation to the user and contact times of 10 to 60 min to 
disinfect surfaces and when immersing items [14]. Rapid 
household disinfectants could reduce transmission in private 
residence and public spaces, such as offices. Detergents, such 
as NP-40 and Triton X-100, have been shown to inactivate 
SARS- CoV-2 at a concentration of 0.5 % [8] and inactivate 
the enveloped hepatitis C virus to below detectable levels at 
even lower concentrations within 1 min [15]. However, envi-
ronmental concerns over Triton X-100 use have resulted in 
calls to produce alternative products (https:// echa. europa. eu/ 
authorisation- list). Virusend is also a detergent- based disin-
fectant, containing N-(3- Aminopropyl)- N- dodecylpropane-
1,3- diamine. Here we have shown that Virusend is able to 
reduce SARS- CoV-2 virus titre by at least 4.0 log10 p.f.u. ml
−1 
in 1 min of contact time making it an effective disinfectant for 
households and public spaces.
An initial obstruction to the work presented here, was the 
need for a high virus titre to show a 4.0 log10 p.f.u. ml
−1 reduc-
tion due to the cytotoxicity of Virusend to Vero E6 cells. The 
limit of detection indicated the point at which cytopathic 
effect in Vero E6 cells is caused by Virusend and not the 
virus. Therefore, to achieve a 4.0 log10 p.f.u. ml
−1 reduction, 
the SARS- CoV-2 culture supernatant had to be concentrated 
after harvesting to give stock titres of 8.4 log10 and 9.8 log10 
p.f.u. ml−1. When a lower stock virus titre of 7.9 log10 p.f.u. 
ml−1 was used, a 4.0 log10 p.f.u. ml
−1 reduction could not be 
demonstrated and would not meet the strict requirements of 
European Standard testing. However, these assays still showed 
a similar trend of inactivation. The reduction with high titre 
virus stock indicates the effectiveness of Virusend, which may 
be necessary to inactivate SARS- CoV-2 in environments that 
are contaminated [16].
Disinfectants tested for use against other members of Corona-
viridae have typically used surrogates to carry out the assays 
more easily. One example of a surrogate virus is murine hepa-
titis virus, a lower risk group pathogen that can be grown 
to high titres and has structural and genetic similarities to 
SARS- CoV [17]. Surrogates are chosen to mimic the target 
virus during inactivation, but the use of surrogates should 
be limited, and the target pathogen should be used when 
possible [18]. Here we have been able to test Virusend against 
an isolate of SARS- CoV-2 collected from a human infection 
and assess the ability of Virusend to significantly reduce the 
titre of the relevant virus.
Current advice focuses on increasing public engagement to 
encourage essential control measures, such as maintaining 
high levels of hygiene in the home [19]. Virusend can reduce 
the strain of demand on current hygiene product resources, 
to be used within private residences, communal public areas 
such as offices and hospital environments [20–22]. The effi-
cacy against SARS- CoV-2 during a short contact time make 
it suitable for rapid disinfection of contaminated surfaces and 
solutions. The development of disinfectants such as Virusend 
Fig. 2. Virusend (TX-10) reduces viral titre in solution by at least 4.0 log
10
 
p.f.u. ml−1 when incubated with high titre (HT) virus inoculum for 1 min 
and 10 min. When low titre (LT) inoculum was used, both incubation 
periods reduced the titre by at least 3.6 log
10
 p.f.u. ml−1, to below the 
limit of detection. Diagonal pattern represents cytopathic effect caused 
by Virusend and solid black represents the titre of infectious virus 
following each treatment. Limit of detection (LOD) (2.0 log
10
 p.f.u. ml−1) 
is shown across the graph with a dotted red line. All columns represent 
mean of n=2,±SD.
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and others is important as we continue efforts to reduce trans-
mission of SARS- CoV-2.
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